Showing results (1-10 of 15) with videos related to
Sort By:
Pageof 2
Cancer|March 1, 1990
Increasing recognition of corticosteroid-induced tumor lysis syndrome in non-Hodgkin's lymphomaJ Sparano, M Ramirez, P H WiernikThe American Journal of Medicine|April 1, 1987
Treatment of the Budd-Chiari syndrome with percutaneous transluminal angioplasty. Case report and review of the literatureJ Sparano, J Chang, S Trasi, et al.Cancer|October 15, 1991
Disseminated aspergillosis after fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantationR Gucalp, N Ciobanu, J Sparano, et al.The Cancer Journal From Scientific American|August 5, 1998
Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's diseaseP H Wiernik, J P Dutcher, A I Einzig, et al.British Journal of Haematology|December 1, 1994
A distinct coagulopathy associated with interleukin-2 therapyL Oleksowicz, M Strack, J P Dutcher, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2E T Walpole, J P Dutcher, J Sparano, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 1998
Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patientsK Hornbuckle, A Chak, H M Lazarus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaM B Atkins, J Sparano, R I Fisher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1991
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanomaJ P Dutcher, E R Gaynor, D H Boldt, et al.Journal of Biological Response Modifiers|December 1, 1990
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2bM Sznol, J W Mier, J Sparano, et al.Pageof 2